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This chapter will explore the impact of spasticity and associated symptoms in hereditary myelopathies 
with a particular focus on Hereditary Spastic Paraparesis (HSP). Hereditary myelopathies include 
syndromes with a genetic cause that involves spinal cord structures. To a variable extent they will 
have upper motor neuron (UMN) symptoms of spastic paraparesis. Importantly in the majority of 
cases structures outside the spinal cord are affected resulting in a diversity of symptom presentation.  
Four main clinical groups can be distinguished 
1
.  
1. Distal Axonopathies of the spinal cord eg HSP 
2. Spinocerebellar Degenerations eg Spinocerebellar ataxia3 (SCA3), Late onset Freidreich’s 
ataxia,  
3. Motor Neuron Disorders eg Familial Amyotrophic lateral sclerosis 
4. Inborn errors of metabolism eg Adrenomyeloneuropathy, Biotinidase deficiency, 
Cerbrotendinous xanthomatosis ,Glycogenosis type IV, Krabbe’s disease Metachromatic 
leucodystrophy and Phenyl Ketoneuria,   
Based on clinical presentation alone it can be often quite difficult to distinguish between conditions. 
People with the complex forms of HSP, for example, can have cerebellar signs and mimic the 
presentation seen in spinocerebellar ataxias. Similarly spinocerebellar ataxias such as SCA3 
(Machado-Joseph disease) can present with significant spasticity and mimic HSP
3
. 
Adrenomyeloneuropathy can sometimes mimic HSP 
4-7
. 
An example of the clinical presentation and management from each clinical group of hereditary 
myelopathies will be described.  The level of understanding of the underlying genetics can vary 
between the different hereditary myelopathies and this will be briefly described. Further, the hereditary 
myelopathies can have quite diverse additional symptoms and pharmacological and rehabilitation 
management which will be described with a particular emphasis placed on evidence for the 
management of spasticity and the upper motor neuron syndrome and its impact on functional ability.  
Distal Axonopathies: Hereditary Spastic Paraparesis 
Prevalence and genetics 
Hereditary Spastic Paraparesis (Strumpell-Lorrain syndrome) has a prevalence of 4-6 per 100,000 
although this can rise up to ~20 per 100,000 in isolated populations  
8
. It is a heterogeneous genetic 
condition. More than 50 gene loci have been identified that can cause HSP 
9
. All types of inheritance 
have been described: Autosomal Dominant (70% of cases), Autosomal Recessive, X Linked and 
maternal mitochrondrial. The age of onset can vary from childhood to late adult life(70 yrs) 
9
 
There is also a high incidence of spontaneous mutations and asymptomatic carriers 
10
. In 
SPAST(SPG4), the most common type of autosomal dominant HSP (40-45% of cases), spontaneous 
mutations to the spastin gene can occur in 13% of cases where symptoms are restricted to the legs
11
. 
Epidemiological studies suggest that 45-67% of autosomal dominant and 71-82% of autosomal 
recessive cases diagnosed with spastic paraparesis have no genetic diagnosis after systematic 
testing 
12
 . 
  
 
Clinical Presentation 
Anita Harding originally described two broad classifications for HSP
13
. The type 1, uncomplicated 
presentation is characterised by the symptoms of lower limb spasticity, hyperreflexia, paresis and a 
positive (upgoing) Babinski response. Additional symptoms of urinary urgency and impaired vibration 
thresholds may also be present. Most cases of autosomal dominant HSP are the type 1, pure 
presentation.  
 In the type 2 presentation people have the same spastic paraparesis presentation as seen in type I 
but with other additional symptoms. Autosomal recessive presentations tend to have a complicated 
presentation and additional symptoms include: 
 Cerebellar ataxia and signs 
 Dementia and cognitive deficits. These are associated with thinning of the corpus callosum. 
 Amyotrophy 
 Peripheral neuropathy 
 Cataracts or pigmentary retinopathy 
 Dry, Itchy skin (ichthyosis) 
 Epilepsy 
The most common types of HSP for each mode of inheritance and pertinent clinical features are 
presented in table x.1 with more rare presentations described in detail elsewhere 
9,14
   
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Gene name & locus Protein Cellular  
Function 
Estimated Prevalence Pertinent features 
Autosomal Dominant (AD-HSP) 
SPAST (SPG4) 2p22 Spastin protein Microtubule 
severing, ER 
morphogenesis, 
Endosomal 
trafficking, 
Inhibition of Bone 
Morphogenic 
Protein signalling 
40-45% of AD cases Childhood-late adult 
Mainly pure HSP 
SPG3A 14q12-q21 Atlastin Intracellular 
trafficking; ER 
morphogenesis 
and BMP 
signalling 
10% of cases Early onset  
Pure HSP 
Autosomal Recessive (AR-HAP) 
SPG11 15q Spatascin Endosomal 
trafficking, 
50% of AR –HSP  Thin corpus callosum; 
cognitive impairment and 
severe axonal 
neuropathy 
SPG7 16q Paraplegin Mitochondrial m-
AAA ATPase 
~ 30 families Variable onset, 
cerebellar signs, optic 
atrophy, neuropathy 
X-Linked 
SPG1 Xq28 L1CAM Cell adhesion and 
signalling, neurite 
outgrowth, 
neuronal cell 
migration and 
survival 
Over 100 cases Cognitive impairment 
hypoplasia of the corpus 
callosum, adducted 
thumbs and 
hydrocephalus 
SPG2 PLP1 Major myelin 
protein in 
oligodendroglia 
<100 cases Quadriplegia; 
nystagmus, cognitive 
impairment, seizures 
Mitochondrial 
No SPG designation ATP synthase 6 Mitochondrial 
localization, ATP 
synthesis 
1 family Late onset disorder 
 
Table x.1: Genetic location; protein and broad cellular function; prevalence and key clinical features. 
Adapted from Salinas et al 2008 and Noreau et al 2014. 
  
Pathology  
Cellular changes 
There has been an increase in the understanding of the changes in neuronal cell function that lead to 
HSP in the last decade. This section will briefly review these changes and more detail can be gained 
from recent reviews of this area 
9,14
.  
Neurons within ascending and descending tracts that connect the brain and the lower segments of the 
spinal cord are over 1 m long. Protein and lipid synthesis and detoxification of harmful substances 
mainly occurs within the cell body and the endoplasmic reticulum(ER)-golgi apparatus system.   A 
system of axonal transport is therefore required that actively transports newly synthesized materials 
from the cell body to the axon and neurotrophic factors and damaged organelles from the axon 
terminal to the cell body 
15
. Axonal transport relies on a cytoskeletal network within the axon made of 
microtubules and actin filaments. Specialized motor proteins bind to and move substances in an 
anterograde or retrograde direction through this network, a process that is ATP dependent i.e. 
requires energy. Genes causing HSP encode proteins that are involved in, the ER-golgi system (e.g. 
ATL-1 (SPG3A); REEP(SPG31); RTN2 (SPG12)) or axonal transport. SPAST (SPG4), for example, 
plays a role in microtubule turnover whilst KIF5A (SPG10) is a member of the kinesin family of motor 
proteins 
9
.  
Molecules can be internalized (endocytosis) or externalized (exocystosis) into the cells or degraded 
by lysosomes. Endosomes are central to the movement of vesicles that contain these molecules. The 
endosomes are linked with the plasma membrane, golgi appparatus and lysosomes. There are 
several genes linked with HSP that encode proteins that are involved in endosomal trafficking (e.g. in 
SPG47 & SPG50-52 components of protein complexes that play a role in secretory/endocytic 
pathway are affected). 
 
All cells require the mitochondria to produce ATP via oxidative phosphorylation. Longer axons with 
their large volume and reliance on axonal transport seem particularly susceptible to disorders of 
mitochondrial function and several genes have been identified that impair mitochondrial regulation 
and cause HSP (e.g. SPG7 encodes paraplegin and SPG13 encode Chaperonin 6)  
 
More recently genes involved in lipid metabolism have been associated with HSP. Lipids are involved 
in energy storage; signaling and in the formation of the plasma and intracellular membranes; which 
cover a large area in longer neurons. Proteins have been described, for example, that are involved in 
lipid metabolism hydrolyzing phospholipids into fatty acids (DDHD2, SPG54) or in the processing of 
gangliosides that are signal transducers within the plasma membrane (eg B4GALNT-1, SPG26). The 
production of the myelin sheath by oligodendrocytes can also be affected and genes causing HSP 
can be expressed in oligodendroglia, but not in motor neurons (eg SPG2) 
9,14
. 
 
  
Overall the pattern suggests that abnormal cellular trafficking/ axonal transport results in degeneration 
of the nerves. The distal most part of the long axons are first affected as molecules need to be 
transported across a long distance and this requires more energy to function  (ie those axons 
projecting to/from the spinal cord segments supplying the lower limb). The recent finding of genes 
being involved in lipid metabolism and in oligodendrocyte function however highlights that a common 
mechanism for all causes of HSP may not be present. Given the heterogeneous presentation of HSP 
more work is required to understand the genotype-phenotype relationship in terms of symptom 
presentation, longitudinal progression and prognosis with intervention.  
 
Changes in descending and ascending tract function 
The pathology in HSP is one of a dying back axonal degeneration predominately affecting the 
corticospinal tracts.  The longer tracts that supply the lower limbs are affected first with shorter tracts 
supplying the trunk and arms being affected later with disease progression 
16
. In keeping with this; the 
lower limb motor evoked potentials (MEPs) following stimulation of the motor cortex using transcranial 
magnetic stimulation (TMS) are either absent or have a higher threshold. Further, when a response is 
present the central conduction time is prolonged. In contrast, hand muscle responses to motor cortex 
stimulation are usually normal 
17-21
. 
The most common MRI change is thinning of the cervical and thoracic spinal cord.  Although, MRI 
and volume based morphometry of the brain may be normal, in SPAST(SPG4) changes are seen with 
Diffusor Tensor Imaging (DTI) 
22
. The DTI reveals white matter changes in the posterior limb of the 
internal capsule and peritrigonal white matter. Frontal lobe white matter changes are more marked 
with longer disease duration
22
. In complicated presentations, such as SPG11, white matter changes 
are more marked and also involve the striatum and brainstem
23-25
.  
Degeneration  of the ascending tracts lying in the fasiculus gracilis of the dorsal columns carrying 
somatosensory information from the lower limbs have also been described
18
. Lower limb 
somatosensory evoked potentials can be reduced in size.  A reduction in vibration threshold is seen in 
~40-60% of patients although interestingly other sensory signs are not commonly seen on clinical 
testing
26
. Similarly, although people with HSP do not usually present with brainstem signs white 
matter loss in the brainstem and abnormal brain stem auditory evoked responses may be seen
27
. 
Degeneration of the spinocerebellar tracts and an associated with loss of volume in the posterior 
fossa have also been described in SPG4
28
 and in complicated forms overt cerebellar signs can be 
seen. Cerebellar signs are particularly prominent in SPG7 and 15. 
Changes in cortical activation with movement 
On fMRI comparisons have been made between activation patterns associated with movement of the 
relatively unaffected hand and ankle movements. Ankle movements in Autosomal Dominant (AD)-
HSP and SPG4 show variable changes with reduced  contralateral sensorimotor cortical activation
29
 
and increased activation of bilateral motor cortex and supplementary and premotor cortex
30
 and the 
  
ipsilateral cerebellum
29
. In two studies normal activation was seen with hand movements 
29,30
 whilst 
Koritnik et al 2009 found increased contralateral sensorimotor cortex and bilateral posterior parietal 
cortex activation with hand movements
31
. The finding that changes in activation may be seen when 
moving an unaffected body part (the hand) is suggestive of functional reorganisation. Therefore, 
changes in cortical activation when moving an affected body part (the ankle) may not be solely related 
to performance differences between people with HSP and healthy controls
31
. As described after 
stroke the different patterns of cortical activation may reflect differences in the degree of pathology 
affecting the sensorimotor system with more widespread, bilateral changes reflecting more severe 
pathology
32
. Patterns of functional re-organisation will also reflect additional factors such as the 
impact of environmental factors and task-related activity.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box1: People’s experience of HSP: Potential benefits of activities and exercise classes 
Bob was a keen runner, he experienced symptoms of pain around the pelvis for 7-8 years before in 1999 
he was diagnosed with HSP type SPG4. With hindsight his pain may have been related to strategies he 
adopted while running to compensate for his increasing stiffness in the legs.  
Following diagnosis Bob trialled Baclofen at a low dose, he described "minor, if any" improvement in his 
walking, and unfortunately he experienced significant and intolerable side effects of fatigue, drowsiness 
and “brain fog”.  Bob stopped taking the baclofen and has not tried any other type of anti-spasticity 
medication. In part this is because he feels that his spasticity still has a low to medium impact on his 
walking but also because he has taken up flying on a regular basis and cannot take baclofen under civil 
aviation authority rules. 
 
Bob's walking difficulties have progressed over time; he currently has difficulty walking in the house and 
tends to cling onto furniture and walls. Outside he uses two crutches, he finds ball point ferrules provide 
the most effective grip when he places his crutches at more acute angles. He drives an automatic car with 
hand controls. 
Bob describes "my legs they refuse to do what my Brain is telling them to do. When walking my knees 
hyperextend, and I get this swelling, pain and tenderness at the back of my knees. I often drag my toes 
and then my foot turns in (inverts) and can roll over." Bob describes his legs as stiff when he walks; he 
does get ankle clonus but very rarely spasms. To compensate for the stiffness in his legs Bob moves his 
trunk a lot while walking; unsurprisingly he has gradually over the years developed low back pain and 
reduced standing balance. He falls occasionally and this tends to be immediately after getting up from 
sitting for a prolonged period (>1 hr) of time. Bob can experience significant fatigue particularly toward 
the end of the day, at these times he may choose to use a wheelchair or rollator. Bob is clear that his 
fatigue is not only related to how much he physically does but also the degree of concentration required 
to safely move and function plus the emotional stress and impact this can have.  
 
For the first 10-15 years Bob found functional electrical stimulation (FES) useful. He worked with the 
clinicians at the National FES centre in the UK where he developed a stimulation pattern of the trunk and 
hip abductors that helped to minimise the excessive trunk sway he experienced while walking  (described in 
2
).  Bilateral stimulation for foot drop was also useful for a time.  Recently Bob decided to stop using FES as 
it was no longer significantly helping his walking. He feels that FES may be more beneficial in the early 
stages of the condition. Instead he uses rigid Ankle foot orthoses; these keep his toes up and stop the 
inversion of his foot.  
Throughout the years of managing his symptoms Bob has remained active and incorporates daily stretches 
for up to 5-10 minutes targeting his plantarflexors, hamstrings and quadriceps. Once a week he attends a 
30 minute exercise class that is run by a trainer who is an ex-Olympic athlete with Multiple Sclerosis. In 
addition Bob has recently discovered 'riding 4 the disabled', he describes this as “fantastic”; as well as 
being enjoyable it helps his balance and core trunk strength. 
 
  
  
Symptoms associated with HSP 
Limb Stiffness:  
Increased limb stiffness is a defining feature of HSP. Hypertonia is  due to a combination of increased 
passive stiffness and enhanced excitability of the stretch reflexes 
33
. People with HSP do not seem to 
have continuous muscle activity whilst trying to rest i.e. “spastic dystonia”. Cramps, particularly of the 
ankle plantarflexors, and lower limb flexor/extensor spasms, elicited by stimulation of the plantar 
aspect of the foot, have been reported.  
Increases in passive stiffness can be seen when the joints of relaxed participants (as confirmed using 
surface EMG) are slowly stretched at speeds that do not elicit a stretch reflex (e.g. at 5
o
/s). Faster 
stretches elicit a short latency stretch reflex that is higher in amplitude compared to healthy controls 
and results in a further increase in stiffness. The difference between the stiffness measured at fast 
and slow speeds is an estimate of the stretch-reflex mediated stiffness and is proportional to the 
evoked EMG response 
33
. The stiffness measured in this way, however, does not take into account 
the impact of passive changes and stretch reflex activity on the viscous response
34
. We have 
recorded stretch reflex thresholds as low as 10
o
/s in people with HSP. This has implications for clinical 
assessments using scales such as the Tardieu scale where the slow stretch that measures the 
passive component  should be purposefully below the stretch reflex threshold (eg a 90
o
 movement 
should take >9s to perform). 
The mechanisms underlying hypertonia in HSP have not been as fully explored as they have been in 
other conditions. Whether increased passive stiffness is associated with an increase or change in the 
amount/ quality of the connective tissue as seen in cerebral palsy and spinal cord injury or is 
associated with shortened muscle fascicles as measured using ultrasound has not been reported to 
date
35,36
.  
A limited exploration of the role of altered spinal cord inhibitory circuits in the genesis of spasticity has 
been performed. Mazzocchio and Rossi (1989) found in people with progressive spastic paraparesis 
and HSP that the Renshaw mediated recurrent inhibition was less than healthy controls. Further,  
there was a smaller reduction in recurrent inhibition with volitional movement compared to controls 
37
. 
This may in part explain why stretch reflex mediated stiffness is not significantly different from healthy 
controls when a muscle is preactivated to ~10% of the maximum voluntary contraction and then 
stretched 
33
. A theoretical explanation based on current evidence from people with HSP and other 
conditions is as follows: At rest reductions in spinal cord inhibitory circuits (eg recurrent and reciprocal 
inhibition) in people with spasticity contribute to a heightened a stretch reflex size
38
. In contrast, with 
preactivation of the muscle inhibitory activity reduces in healthy participants but does not reduce as 
much in people with HSP 
39
. This could result in similar values of spinal cord inhibition when the 
muscle is preactivated and thus a similar response to muscle stretch. Further, the overall stiffness is 
in part mediated by active cross bridge formation resulting in similar stiffness values between the two 
groups. From a practical basis, as other groups have highlighted, this has implications for the role of 
spasticity in causing difficulties with functional movements
40,41
. The high resistance to movement 
  
when a resting muscle is passively stretched during a clinical examination on a treatment couch may 
therefore not correspond to the resistance occurring when the same muscle is stretched during a 
functional task when it is pre-activated (see also impact on functional ability below). 
Changes in other spinal cord inhibitory circuits such as reciprocal and presynaptic inhibition; the 
development of mototneuronal plateau potentials and changes in 1a afferent neurotransmitter release 
that occurs with repetitive stimulation (reduction in postactivation depression) reported in other UMN 
syndromes have not been assessed in people with HSP. Recent work has found that there are 
differences in the pattern of inhibitory spinal cord circuit alterations in adults where spasticity 
developed over the developmental period (people with cerebral palsy) compared to adults with 
acquired spasticity (people with adult onset stroke)
42
. In adult cerebral palsy a  reduction in 
presynaptic inhibition is observed but there are no reductions in reciprocal inhibition in contrast to the 
person with adult acquired spasticity
42
. Given that many types of HSP have an onset in early 
childhood (1 yr and above
43
), it would be interesting to compare spinal cord inhibitory circuitry in early 
and late onset HSP and whether this leads to any quantifiable impact on the response to muscle 
stretch and function.  
Cortical modulation of stretch reflexes is also abnormal in HSP. Usually in healthy control participants 
the soleus H reflex is facilitated by prior stimulation of the motor cortex leg area at interstimulus 
intervals of 10 and 20 ms and 70-90ms. This early facilitation is lost in people with HSP and a new 
form of facilitation at an interstimulus interval of 40 ms is seen. This was felt to reflect the longer 
desynchronised central conduction times in HSP
44
. These changes were not related to motor function. 
Whether soleus H reflex modulation during stance and swing phase of walking is disrupted in HSP as 
described in other conditions with spasticity is currently unknown. However, phase dependent 
modulation of cutaneous reflexes elicited in tibialis anterior and biceps femoris by stimulation of the 
sural nerve are smaller in HSP 
45
 
 
 
  
 
Figure x.1 Cortical modulation of the H reflex was assessed by stimulating the cortex using TMS at 
different inter-stimulus intervals (ISI) in the range 0-100 ms prior to stimulating the H reflex. The H 
reflex responses for a health participant (A) and person with HSP (B) are shown with ISI 0-90 ms 
superimposed. A comparison of the control (n=10) and HSP (n=10) groups show that early facilitation 
of the H reflex at ISI =10 and 20ms is less in HSP possibly reflecting  longer desynchronised central 
conduction times (adapted from 44) 
 
As with other conditions the central changes resulting in spasticity in HSP are unclear. The degree of 
spasticity (as measured by the Modified Ashworth test) is negatively correlated to activity in 
Brodman’s area 4 and 1-2-3 measured using fMRI during ankle movements
29
. However, here 
spasticity may simply be a marker of disease severity and not reflect a causative relationship. The 
cortical silent period is an interruption of a voluntary muscle contraction following stimulation of the 
contralateral motor cortex using TMS. Earlier inhibition is in part spinally mediated whilst later 
suppression reflects the activation of GABAB (gamma-aminobutyric acid) receptor-mediated cortical 
inhibitory circuits
46
. In HSP (SPG4) the cortical silent period is shortened indicating reduced activity of 
motor cortical inhibitory interneurons. The reduction in the cortical silent period in turn was associated 
with the degree of spasticity as measured by the Ashworth scale
47
. This has correlates in stroke and 
Amyotrophic lateral sclerosis (see below), where a shortened cortical silent period is associated with 
the development of spasticity
48-50
. Using paired-pulse TMS other groups have found an increase in 
intracortical facilitation in AD-HSP
51
 . The increase in intracortical facilitation may reflect a reduction in 
GABA-interneuronal activity (in keeping with the shortened cortical silent period) but may also reflect 
an increase in glutamateric transmission or a compensatory mechanism to increase corticospinal 
transmission. Interestingly the changes in intracortical facilitation were found in areas controlling hand 
  
muscles. Thus, the association between changes in cortical silent period and spasticity may either be 
causative or reflect the co-occurrence of paresis and spasticity and compensatory mechanisms to 
maintain / increase corticospinal output
51
. 
Paresis: 
Lower limb weakness co-occurs with spasticity in HSP. Muscle strength is commonly described as 
being clinically less affected than that seen in other acquired UMN syndromes (Salenius, 2008). 
Objectively isometric maximal voluntary contraction of lower limb muscles in HSP has been measured 
using dynamometry
52
. The isometric contraction aimed to avoid reductions in applied torque by 
stretch reflex activation in antagonist muscle groups that may occur during isokinetic testing. Isometric 
muscle strength was lower in all lower muscle groups tested. When combined flexor and extensor 
muscle strength at the ankles, knees and hips was compared to healthy controls there was a proximal 
to distal gradient of weakness.  
 
 
 
Figure x.2 Differences in isometric strength between people with HSP (n=20) and Healthy Controls 
(n=18) 
 
The two muscles most affected were the ankle dorsiflexors and the hip abductors that were on 
average ~50% the strength of that seen in age and gender matched controls. 
52,53
. Significant 
differences in the ratio between agonist-antagonist muscle strength are also seen. The ratio of hip 
abductor/hip adductor strength, for example is significantly lower in people with HSP. This muscle 
imbalance with relative sparing of some muscle groups such as the hip adductors may account for 
  
“spastic gait patterns” such as scissoring while walking rather than being attributable to spasticity per 
se.  
Sensory loss: 
Vibration threshold is increased in ~40% of people with HSP and is greater distally at the hallux
26
. 
This may reflect degeneration of the fasiculus gracilis but also spinocerebellar degeneration as 
conscious perception of vibratory signals may be mediated by both pathways
54,55
.  
Bladder:  
Bladder dysfunction is seen in ~75% of people with HSP 
56,57
but is often not reported. A retrospective 
review revealed symptoms of urgency (51.0-72.4%), frequency (55.1-65%), urinary incontinence 
(55.2-69.4%), hesitancy (51.7%) and incomplete bladder emptying (36.75%)
56,57
 . Urodynamic 
analysis revealed detrusor overactivity in 82.7% of cases and detrusor sphincter dyssynergia in 65.5% 
of cases. Detrusor overactivity was associated with higher post-void residuals and symptoms of 
urinary frequency and nocturia
56
. 
Bony changes 
As HSP is a condition that can have an onset during development there is the potential for bony 
change similar to that seen in CP or Freidriech’s ataxia / Charcot-marie tooth disease. These may 
contribute to motor dysfunction. In children with HSP hip joint motion in the transverse plane while 
walking is similar to typically developing children in contrast to children with Cerebral Palsy and 
spastic Diplegia (CP-SD) who demonstrate high internal rotation. Although not confirmed by X rays 
this suggests that in early onset HSP there is a physiological correction of femoral anteversion 
compared to children with CP-SD in whom symptoms are present from birth.  Pes cavus is commonly 
seen in HSP. The high arched foot and altered heel alignment could affect the line of pull of the 
plantarflexors reducing the effective plantarflexor torque during the push off phase of walking. People 
with HSP commonly have an increased lumbar lordosis and, as highlighted below, trunk motion is 
often increased while walking; this is associated with a high incidence (>75%) of low back pain. 
Fatigue 
As with other long term neurological conditions fatigue is common and shows similar complexities. 
The degree of fatigue, for example, is not always related to the amount of physical activity performed 
and cognitive tasks, stress and anxiety may also impact on fatigue and walking performance.  
Mood and Quality of Life 
Reduced mobility is also associated with the presence of depression as measured by the Beck 
depression inventory with 28/48 (58%) of cases showing depression which in 75% of these cases was 
mild
58
.Quality of life is reduced in people with HSP and is lower in people with more severe disease 
(as measured by the Spastic Paraplegia Rating Scale
59
); reduced walking ability and the presence of 
a type 2, complicated presentation 
60,61
.  
  
Impact of Spasticity and associated symptoms on Functional ability 
People with HSP in particular have difficulties with walking, balance and falls. Discussion and focus 
groups with people with HSP in the UK (n=30 Unpublished observations, 
62
,) have highlighted the 
difficulties with functional tasks. Understanding these perceptions are important when elucidating the 
relative impact of symptoms such as spasticity and limb stiffness. People with HSP find that walking 
backwards (such as stepping back to open a door), walking on uneven terrain and on cambers/slopes 
particularly difficult. Falls can be precipitated by a loss of balance but also by tripping caused by foot 
drop as the foot either contacts external objects or catches the other foot/leg in swing phase. Walking 
is reported to require increased attention as people have to concentrate on their foot placement and 
performing concurrent tasks (ie walking and talking) can be difficult. Walking and lower limb stiffness 
was often (> 50% of respondents) modulated by the environmental temperature with stiffness higher 
and walking more difficult in cold weather compared to warm weather although very hot, humid 
climates were reported to cause excessive fatigue and limit walking ability. 
Balance 
Causes of poor balance in HSP could be due to multiple factors such as impaired central afferent 
and/or efferent signal processing, poor central integration of multi-sensory afferent signals, spasticity 
and secondary changes in muscle strength and musculo-tendinous stiffness.  
People with HSP show delayed lower limb muscle responses to forward and backward postural 
perturbations
63
. This is presumably in part due to dorsal column-medial leminiscal and spinocerebellar 
degeneration leading to impaired processing of afferent signals that detect the onset, size and 
direction of the perturbation. An important role in afferent as opposed to efferent pathway pathology in 
causing balance dysfunction is supported by the fact that the onset of the lower limb muscle response 
following a perturbation is normalised when the perturbation is paired with an acoustic signal elicits a 
startle response 
64,65
. This suggests that the efferent pathways mediating the startle response 
(presumed to be the reticulospinal tract) are intact. An improvement in muscle onset times with a 
startle response is also seen in healthy controls but it is more marked in people with HSP
64,65
. 
Enhanced startle responses have been reported following pontine stroke where they are felt to arise 
due to a disruption of the cortical control of lower brain stem centres
66
. As many cortical projections to 
the brainstem arise from collaterals of the corticospinal tract a similar cause of enhanced responses 
to a startle could occur in people with HSP. The relative importance of abnormal processing of 
afferent information is supported by other groups that have found that higher degrees of standing 
postural sway are  associated with increased vibratory thresholds
53
. 
Muscle weakness also contributes to poor balance. Greater postural sway in the mediolateral plane is 
associated with greater weakness in the hip abductors. Greater antero-posterior sway during quiet 
standing and following a forward perturbation is correlated with greater weakness in the ankle 
plantarflexors 
53,67
.  
The role of spasticity in mediating imbalance remains unclear. de Niet et al 2012 found that greater 
stffness (as measured by the modified ashworth scale)  resulted in greater imbalance following a toe-
  
up perturbation in HSP 
67
. This perturbation stretches the ankle plantarflexors and requires a 
stabilising response in the tibialis anterior. Interestingly the strength of the tibilais anterior (as 
measured using manual testing) did not affect the response size. In contrast Marsden and Stevenson 
2012 measured ankle passive and stretch reflex mediated stiffness in people with HSP using motor-
driven perturbations. They found that greater total ankle stiffness and stretch-mediated stiffness were 
associated with less antero-poterior sway
53
. They suggested that higher ankle stiffness may serve to 
aid stability. 
 
Walking: 
Walking difficulties is a characteristic feature in HSP. A study of 194 people with HSP in Norway 
highlighted that 31% were classified as having mild symptoms; 32% as walkers that were unable to 
run; 25% as walkers dependent on walking aids and 11% as wheelchair dependent
43
.  
People with HSP walk with a slower velocity, have a smaller step length, an increased stride and step 
time and a larger base of support 
68-70
. The walking pattern in HSP has been characterised in several 
studies. Using cluster analysis Wolf et al (2011)
70
 identified 5 clusters similar to that described 
previously for children with cerebral palsy 
71-73
 (figure x.1): 
 
 
  
 
Fig x.1 Walking patterns in people with HSP and CP highlighting different types of gait presentation.  
Crouch gait – characterised by increased hip and knee flexion during stance phase 
Recurvatum – characterised by increased knee hyperextension in midstance 
Stiff knee- characterised by reduced knee motion in swing phase 
Jump Knee- characterised by increased knee ﬂexion at loading response and almost normal knee 
function later in the gait cycle 
Normative- a gait cycle similar to normative data obtained from healthy control participants. 
 
 
 
 
 
  
Comparisons have been made between people with HSP and spastic diplegia due to cerebral palsy 
(CP-SD). In part this is driven by the desire to identify characteristics that may aid in the differential 
diagnosis of CP-SD. The proportion of people with prolonged knee and hip extension characteristic of 
a recurvatum pattern and prolonged ankle plantarflexion in stance phase was higher in people with 
HSP
68,70
. Increased amplitude and speed of trunk movement in the sagittal plane was also greater in 
people with HSP compared to people with CP-SD who tend to show higher shoulder motion (flexion / 
extension and elevation) akin to the  “guarding” seen by infants in the early stages of walking
69
 
There are several impairments that correlate with the characteristic walking patterns seen in people 
with HSP. For example, greater stiffness in the hip flexors, as assessed using the Ashworth scale, is 
associated with reduced active range of movement and slower walking speeds. Other studies have 
focused on specific aspects of the gait cycle such as ankle equinus and stiff knee gait as outlined 
below.  
 Early studies modelling walking have highlighted that movement of the leg in swing phase from knee 
flexion through to knee extension in terminal swing is in part passive in nature reflecting the motion of 
a multi-linked pendulum moving as a result of torques generated at the end of stance phase
74
. More 
recent modelling studies have highlighted the importance of muscle activity during swing phase in 
regulating the motion of the leg
75,76
.  Eccentric lengthening of the rectus femoris muscle, for example, 
controls the initial rapid knee flexion at the start of swing phase whilst hamstring muscle activity acts 
to control the subsequent extension of the knee at the end of swing phase. Modelling studies have 
also highlighted the importance of the ankle plantarflexors and hip flexors in generating torques that 
initiate swing phase
77,78
.  
Using dynamometry to produce motor-driven perturbations and test strength Marsden et al (2012) 
explored impairments that were associated with reduced knee flexion; the stiff knee gait. Of the 
variables prospectively assessed (knee extensor passive and stretch-mediated stiffness, ankle 
plantarflexion and hip flexion strength) they found that increased knee extensor passive stiffness and 
weakness in the ankle plantarflexors were associated with reduced ankle power and an increased 
knee extensor moment in preswing and in turn reduced knee flexion velocity and amplitude
52
. Lower 
knee flexion velocity at the start of swing phase was also associated with less knee extension at the 
end of stance phase reflecting the impact on the pendular motion of the leg (unpublished 
observations).  
This study highlights the relative importance of passive stiffness and weakness in producing stiff knee 
gait. It also brings into question the relative role of knee extensor spasticity in limiting knee motion. 
Although knee extensor spasticity was significantly higher in people with HSP compared to controls 
this was not correlated with a limitation in knee flexion
52
. This could reflect the fact that with activation 
of the muscle at the end of stance phase the stretch-reflex mediated stiffness is normalised, as 
described above. However, the lack of correlation could also reflect the methods used. Knee extensor 
stiffness was measured with the participant in supine while they rested / preactivated the muscle. 
Although this reflects the assessment of limb stiffness in clinical practice stretch reflex activation 
  
during walking was not assessed. In other UMN conditions it has been reported that the stretch reflex 
activity in the knee extensors normally modulates while walking being higher in amplitude during 
stance as opposed to swing phase. This is felt to reflect changes in the degree of muscle activation 
(and so the excitability of the motorneurone pool) but also modulation in pre- and post-synaptic 
inhibitory circuits within the spinal cord
79
. In other conditions with spasticity this degree of modulation 
is reduced
80
. Therefore stretch reflex behaviour at rest may not reflect that seen during functional 
movements. However, in support of the finding of a lack of relationship between knee extensor 
spasticity and stiff knee gait Piccini et al (2011) recorded less rectus femoris activity  while walking in 
children with HSP in contrast to those with CP-SD where excessive activity was noted
69
. Other 
studies measuring spasticity using motor driven stretches have highlighted a potential role of 
spasticity in limiting joint motion while walking. Higher plantarflexor stiffness (due to a combination of 
passive and stretch-mediated stiffness) was associated with reduced ankle dorsiflexion during 
walking
2
. This effectively lengthens the limb during swing phase and contributes to the trips and falls 
seen in people with HSP.  
Central motor conduction time to leg muscles as assessed using TMS does not correlate with gait 
parameters in HSP
81
. This is in keeping with studies in stroke suggesting that corticospinal tract 
damage (as determined via DTI, MRI and TMS) may not be  key determinant in limiting walking ability 
82,83
 unlike its fundamental role in fine fractionated finger motion and hand function. This may be 
because walking is more dependent on subcortical circuitry 
84
 and/or because people are able to 
compensate for weakness by using other body segments to aid progression and by altering lower limb 
alignment relative to the ground reaction force to aid stability in stance .  
There are several compensatory strategies that people with HSP seem to adopt to aid walking. 
Increased hip flexion during swing phase is associated with greater toe clearance 
2,69
. The excessive 
trunk and pelvic motion seen in many people with HSP may also aid leg swing
69
. Higher trunk and 
pelvic horizontal and coronal motion is seen in people with less flexion of the knee during swing 
phase (unpublished observations) and may aid leg swing. Knee recurvatum brings the ground 
reaction force in front of the knee and could be a compensatory strategy to compensate for weakness 
in antigravity muscles such as the knee extensors which are more frequently MRC grade 1-2 a nd 
weaker compared to people with CP-SD
68,69
. Alternatively, knee hyperextension may be related to an 
increase in the plantarflexion/knee extension couple associated with increased plantarflexion stiffness 
as is often reported in CP-SD
69
. Determining the exact reasons for knee hyperextension in HSP  is 
important in guiding treatments as reducing the ability to hyperextend the knee (eg with splinting) may  
result in instability in the presence of knee extensor weakness 
69
. 
These potential compensatory strategies may not be wholly beneficial. Increased trunk motion 
associated with an increased lumbar lordosis, anterior tilt of the pelvis 
69,70
and tight hip flexors may 
contribute the high incidence of low back pain. Further, knee recurvatum can be associated with 
stretching of the soft tissue on the posterior aspect of the knee and subsequent knee pain.  
 
  
Outcome measurement 
There is a relative paucity of disease-specific rating scales for HSP. The Spastic Paraplegia Rating 
Scale (SPRS) described by Schule et al 2006  is a standardised, 13 item tool that combines 
measures of walking performance, stair climbing, rising from a chair, lower limb spasticity, muscle 
power, range of movement, pain and bladder and bowel function. An inventory of complicating signs 
and symptoms differentiates between pure and complex forms of HSP.  The SPRS takes 15 minutes 
to complete and higher scores indicate worsening disease severity. The SPRS has high levels of 
inter-rater agreement (intraclass correlation coefficient=0.99), internal consistency (Cronbach α=0.91), 
criterion (r=0.83, p <0.001) and construct validity 
59
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interventions 
Pharmacological and surgical treatment of spasticity 
The role of anti-spasticity medications in the management of spasticity and function have been 
explored in several studies. However, they show considerable bias with studies showing low sample 
sizes, a lack of control groups and blinding. A retrospective review of botulinum toxin injections into 
the hamstrings, hip adductors and gastrocnemius of 12 children (6.9 yrs+/- 4.9yrs) with HSP reported 
a decrease in stiffness (as measured by the Ashworth scale) and improvement in motor function (as 
measured by a 2.4 +/-3.2 change in the Gross Motor Function Measure GMFM) over an average 13.2 
month (11.0) period
85
. The GMFM is an ordinal measure assessing movement ability in lying; sitting; 
standing and walking. Given the lack of a control group the results on function should be interpreted 
with caution. Comparing the results to children with CP of the same age and severity (as measured by 
the Gross Motor Classification Scale) the GMFM changes by ~5 points over a 1 year period
86
 as the 
child develops new skills. Therefore, these results could simply result from changes in motor function 
with development. Subjectively 11/12 parents felt there was an improvement in motor function with 
Box2: People’s experiences of  HSP: The benefits of ITB and keeping active 
Pam describes symptoms of HSP occurring throughout all of  her life, she was finally diagnosed 18 
years ago, after 2 years of investigations, she was 33. Within her family, her grandmother, mother 
and brother all experience walking difficulties She does not have a genetic diagnosis and does not 
feel that having one would make much difference. 
 
Pam walks with one stick, she describes poor balance and the need to rest every 5 minutes as her 
legs become tired. She has difficulty climbing and descending stairs. Pam has lost confidence in her 
walking and falls about once a week. She tends to catch her toes as she lifts her feet, " I go straight 
down and am unable to use my arms to save myself".  Pam explains that her legs can feel both stiff 
and weak and is particularly marked after any activity. She used to do stretches but did not find them 
helpful,  instead she explains "I find a couple of hours out in the afternoon wandering around the 
shops is more beneficial than being sat in the house doing exercises". 
 
Pam has an intrathecal baclofen pump that was implanted 1 ½ years ago. She found oral Baclofen 
made her very sleepy but this is no longer a problem with the ITB pump. Since having the pump Pam 
feels she stoops less and has a more upright posture when walking.  
 
 
Before the operation she had symptoms of urgency (“wanting to go quickly”). In the last year Pam 
feels her bladder function has deteriorated. She now feels she wants to go but the urinary flow has 
stopped leading to her having an accident afterwards (symptoms akin to bladder sphincter 
dyssynergia). She has her pump filled locally and finds this very convenient and sees a Rehabilitation 
consultant once a year 
 
 
 
  
2/12 reporting an improvement in activities of daily living
85
. A series of 19 case reports in adolescents 
and adults with HSP described the use of Botulinum toxin injections into multiple muscle groups (hip 
adductors. Iliopsoas, plantarflexors, rectus femoris and posterior tibial). Reductions in stiffness were 
widely reported and this could be associated with changes in posture (e.g. the ability to cross the legs) 
and function (e.g. walking) although 7/19 reported no or minimal global subjective effect. The 
functional effects were more marked in people with mild or moderate spasticity. Increased weakness 
was reported in 3/19 people which was felt to be an unmasking of underlying weakness following 
spasticity reduction
87
. Similar effects have been reported in 15 people with HSP who had injections 
into the hip adductors, plantarflexors or posterior tibial muscles. Reductions in adductor and 
plantaflexor spasticity were reported and 6/15 showed an improvement in walking velocity. The 
Functional Ambulation Category (FAC), and Rivermead Motor Assessment  did not change
88
. 
Oral anti-spasticity medications are frequently used in HSP including baclofen and tizanidine. To date 
there have been no trials of these medications in HSP. Clinical opinion suggests that they can be 
associated with widespread fatigue and improve spasticity in only a limited number of people 
87,88
. 
Gabapentin is a GABA agonist originally used to treat epilepsy and neuropathic pain. Its effects were 
assessed in  a cross-over trial of 10 people with HSP (SPG4) 
89
. Blood samples confirmed a 
therapeutic dose (4000 mg/day) was present during the intervention periods. There were no 
differences between gabapentin and placebo in terms of subjective report of disability, clinical 
assessment of lower limb reflexes; strength or limb stiffness, walking scales or motor intracortical 
excitability as measured using TMS. In an open label trial of methylphenidate in people with sporadic 
and HSP no effect was found on walking speed or walking parameters after a 6 month period of use
90
 
Intrathecal baclofen has the advantage of reducing side effects associated with oral baclofen such as 
weakness and fatigue. Double blind administration of a bolus of baclofen into the intrathecal space is 
associated with a clear reduction in stiffness and deep tendon reflexes that is maintained with long 
term administration
91
. However, the impact on walking has only been assessed using case studies. 
Without the use of control groups or single case study designs with multiple baseline measures these 
studies clearly present with a risk of bias although they do highlight some potential benefits and 
limitations. Improvements have been seen in walking speed, walking kinematics/kinetics and angle-
angle plots with either a single bolus or continuous infusion over time 
92-94
. Other movements such as 
squatting also show a normalisation with a change from co-contraction to a reciprocal pattern of lower 
limb activation with a bolus of baclofen 
95
. The timing of administration and the titration of the ITB 
dose is important. Satisfaction is higher in people in whom the implant occurs while they are still 
ambulant. Initially people can report weakness
96
. The reported therapeutic dose has varied from 60-
264 micrograms per day and may vary depending on the underlying pattern of symptoms
91
. As well as 
potentially impacting on walking ability ITB may improve sleep time and efficiency and reduce periodic 
leg movements. These improvements reported in a study on 20 people with spasticity of whom 1 had 
HSP; they were not accompanied by any change in lung function tests or sleep related respiratory 
patterns
97
. Bladder function has also reported to improve with ITB 
98
. 
  
In four adults with pure (type 1) hereditary spastic paraparesis (genetic diagnosis not given) the 
effects of selective dorsal root rhizotomy from L2-S2 nerve roots have been described. Following the 
procedure reductions in tone and spasm frequency accompanied a subjective improvement in 
standing posture, stability and walking with a decrease in scissoring of gait 
99
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box3: People’s experiences of HSP:  HSP across the lifespan 
BIll is 54 years old, he has experienced symptoms since birth. Up to the age of 27 his diagnosis was 
described as a “best estimate" of cerebral palsy. There was no known family history in previous 
generations. When his elder brother became affected in his early 30s this acted as a trigger for Bill to get 
‘re-diagnosed’. At the time there was no specific gene testing but they were both given the diagnosis of 
HSP. Gene testing followed later with a positive diagnosis of SG4. Since that time Bill's Mother (aged 80) 
has tested positive for SPG4. She had experienced difficulty with mobility since her mid-60s but not to the 
same extent as her son's, she has recently had a fairly severe stroke and now is unable to weight bear. 
Another brother has also recently tested positive for SPG4 but so far is not showing any symptoms. 
 
Bill walked without aids for several years, people would often comment ‘we don’t know how he walks, but 
he does’. Bill describes “typically I used to aim at where I needed to be, and grabbed hold of walls / 
furniture / shoulders to get there”. He started to use a wheelchair at the age of 38. It had been suggested 
a number of years previously, but he had resisted. It turned out to be of great benefit, enabling outdoor 
mobility that he had previously lost. Bill now uses a wheelchair for most of his community mobility, at 
home he uses elbow crutches, but is limited to very short distances and describes his walking as “both 
uncomfortable and very slow”. He tends to swing on his crutches, rather than take steps. Bill can just 
manage the stairs so long as there are hand rails on both sides, but it too is very effortful and slow. 
 
A significant problem continues to be spasticity and painful spasms, these are problematic in the day, but 
also at night causing sleep disturbance.  This exacerbates his fatigue which is an ongoing symptom 
requiring management. He also experiences a constant ‘ache’ and the feeling that "my muscles never 
properly relax." Bill did experience bladder frequency & urgency, this is now managed with self-
catheterisation.  
 
Bill had an Intrathecal Baclofen Pump implanted in 2011. He describes this as very beneficial, he has 
noticed a big improvement in his spasticity, with the drug now delivered over 24 hours without any of the 
unwelcome side effects of the oral medications. He had tried most of the anti-spasticity medications and 
had found them problematic mostly for two main reasons. "The dose required to positively affect my legs 
caused too much weakness in my upper body – which was a key part in enabling me to get around. So 
overall the drugs tended to make me less mobile and secondly they caused fatigue and I needed to sleep 
most afternoons’. 
 
Bill has tried various other treatments over the years. Plaster casts to stretch his calf muscles were a 
regular feature in his younger years. He remembers " hating those casts". He would wear casts for 6-8 
weeks a year, with them being changed weekly to increase the stretch. At other times in his childhood he 
had removable plaster casts for regular but intermittent use. 
 
 
Bill has tried Functional Electrical Stimulation but did not find any benefit from it unlike other HSP support 
group members. He has found physiotherapy, exercises and stretching to be “very beneficial”, but finds 
physiotherapy difficult to get to. He regularly stretches and feels it is important for stretching at home to 
become ‘routine’. Bill has invested in a ‘Theratrainer Cycle’ and an ‘EasyStand’ hydraulic chair, he aims to 
use each of them for 30 mins once a week. 
 
 
  
 
Physical Interventions 
Physical therapy is commonly prescribed for people with HSP. Techniques include progressive 
resisted exercises, stretches, task related training of walking and interventions targeting 
cardiovascular fitness
100,101
. Although focus groups highlight that people feel they benefit from 
physical therapy there have been no studies exploring their benefits. Given the paucity of evidence 
following systematic reviews for techniques such as stretching on spasticity and passive stiffness in 
other upper motor neuron syndromes it is important that this is evaluated
102
. 
Orthoses have been prescribed to aid foot drop caused by combined anterior tibial weakness. If  
plantarflexor spasticity/stiffness is marked the orthosis often needs to be quite rigid; hinging the ankle 
joint in these cases can aid stair descent which requires a degree of ankle dorsiflexion. The aim of an 
orthosis has to be clearly defined. Some people with HSP may hyperextend their knee to compensate 
for knee extensor weakness in these cases reducing ankle plantarflexion may actually enhance 
instability by bringing the ground reaction force behind the knee joint requiring knee extensor 
activation 
69
. 
Marsden et al (2013) investigated the immediate effects of functional electrical stimulation (FES) of 
the common peroneal nerves bilaterally to aid foot drop during swing phase
2
. Participants were long 
term (>1yr) users of FES with either sporadic or hereditary spastic paraparesis. Walking speed 
increased with FES by 10% compared to no stimulation; there was no effect on walking efficiency as 
measured using the physiological cost index. Some participants had novel patterns of stimulation 
including stimulating the contralateral hip abductors and ipsilateral trunk extensors at the start of 
swing phase that also aided the clearance of the toe during swing phase
2
. Chronic electrical 
simulation to improve muscle strength has also been reported in one case with familial spastic 
parapresis. Here the quadriceps and tibialis anterior muscles were stimulated bilaterally 2-3x/week 
over 3 months. A 27% improvement in walking speed was observed with an improvement in the 
degree of crouch in stance phase
103
. Further work is required to ascertain whether there are long term 
carry over effects of FES and whether isolated electrical stimulation produces objective changes in 
muscle strength and function. 
Hydrotherapy offers people with HSP the opportunity to use the buoyancy and drag of water to 
perform range of motion, strengthening and endurance exercises and to take advantage of the effects 
of warming (see below). A 10 week hydrotherapy (5 weeks group, 5 weeks individual with sessions 
x2/week) program was assessed in 10 people with HSP. Following the program the participants 
showed reduced total range of movement at the ankle, knee and hip in the transverse plane, 
enhanced hip internal rotation and an increase in hip extension moment in initial stance phase while 
walking.   This was interpreted as being due to an increased use of compensatory strategies (see 
above) to aid foot clearance rather than a change in underlying impairment
104
.  
  
The effects of localised changes in temperature of neuromuscular function, foot tap speed and 
walking ability have been explored in HSP by Denton et al 2015 (in submission). On separate days 
the temperature of one shank was raised (~10
o
c ) or lowered (~13
o
c) using a temperature controlled 
water bath. Increases in lower limb peripheral nerve conduction velocity, the rate and amplitude of 
ankle muscle force output and a reduction in plantarflexor stretch-reflex mediated stiffness was 
observe with warming with opposite effects being seen with cooling. Further, despite one leg only 
being targeted there was an increase in maximal walking speed with warming (~10%) and a similar 
sized decrease with cooling. Many of the effects on temperature were similar in magnitude in people 
with HSP compared to matched controls. However, the decrease in walking speed with cooling was 
more marked in people with HSP. This was interpreted as resulting from the fact that due to bilateral 
lower limb involvement a slight reduction in neuromuscular function in one leg has a marked effect on 
functional ability. In contrast healthy participants were able to compensate for this by using other body 
parts (eg trunk and opposite leg). These findings support the subjective view of people with HSP that 
their symptoms are worse in cold weather and suggests that strategies such as the use of insulating 
garments in colder weather, external warming (eg with heat packs , hydrotherapy) or exercise to 
increase internal temperature may aid stiffness and mobility. 
Service Delivery 
Due to the rarity of HSP knowledge of the condition and service delivery for this condition can be 
variable. Poor local knowledge about the condition and its management by health care professionals, 
difficulty in accessing specialist services (in terms of availability and time), poor service co-ordination 
(eg between neurologists, genetic counsellors and allied health professionals) and access to evidence 
based treatments were issues raised in focus groups of people with HSP in a rural setting within the 
UK. Further, focus groups with carers highlighted the often large and continual burden placed upon 
them and the need to establish supportive networks
62
. One particular source of network support are 
the national support groups present in many countries that provide educational and emotional support 
throughout the disease process 
 
Spinocerebellar Degenerations:  
 
Autosomal Dominant  
Anita Harding originally described three classifications of Autosomal Dominant Cerebellar Ataxias 
(ADCAs) 
13
. Type 1 is characterised by a cerebellar syndrome with ophthalmoplegia, pyramidal or 
extra pyramidal signs, cognitive impairment or peripheral neuropathy. This presentation is caused by 
variable degenerations of the cerebellum, basal ganglia, cerebral cortex, optic nerve, pontomedullary 
systems, spinal tracts, or peripheral nerves. Pigmentary retinopathy accompanies a variable 
presentation of cerebellar and extra-cerebellar signs in ADCA II, otherwise similar to ADCA I. A third 
group, ADCA type III includes relatively pure cerebellar ataxias where the degenerative process is 
  
limited to the cerebellum. Clinically characterised ADCAs are now increasingly also referred to as the 
spinocerebellar ataxias (SCA) denoting the genetic classification system. There are numerous SCAs 
identified and some labels reserved, as outlined in table x.2. The SCAs are clinically heterogeneous 
but they often present with progressive cerebellar ataxia. This usually starts with symptoms of ataxia 
while walking and poor balance followed by symptoms of limb ataxia, dysarthria and visual problems. 
Visual problems, although often not the first signs/symptoms detected by the patient have been 
proposed as an early sign, since the advent of pre-symptomatic genetic testing
105
. Visual problems 
can be caused by either oculomotor abnormalities secondary to cerebellar degeneration (eg saccadic 
dysmetria, impaired smooth pursuit and nystagmus) or non-cerebellar causes (eg maculopathy, gaze 
palsies, slowed saccades). Maculopathy can precede the appearance of the cerebellar ataxia in 
SCA7 by up to 20 years
106,107
. Cerebellar degeneration often is accompanied by involvement of the 
brainstem and spinal cord although relatively isolated cerebellar degeneration can occur (eg in 
SCA6)
108
. A description of the pathology, clinical presentation and intervention of SCA3 the most 
common SCA presenting with additional UMN signs will be described.  
 
Table x.2: Adapted from Giunti and Wood, 2007 
109
 
Gene name 
(chromosome location 
and locus) 
Protein & mutation Pertinent features 
ADCA I  Cerebellar syndrome plus ophthalmoplegia, pyramidal or extra 
pyramidal signs, cognitive impairment or peripheral neuropathy 
SCA1 (6p22.3 ATXN1)  Ataxin 1 CAG repeat  Ataxia,pyramidal signs,,neuropathy, ophtalmoplegia 
SCA2 (12q24.13 
ATXN2) Ataxin 2 CAG repeat  Ataxia,slow saccades,neuropathy 
SCA3 (14q32.12 
ATXN3)  Ataxin 3 CAG repeat  Ataxia,pyramidal signs,ophthalmoplegia, neuropathy,dystonia 
SCA4 (16q24-qter 
SCA4)  Unknown Ataxia,sensory neuropathy 
SCA8 (13q21 
KLHL1AS)  Kelch-like 1 CTG repeat  Ataxia,sensory neuropathy 
SCA9 Reserved  Unknown 
 SCA10 22q13.31 
ATXN10  Ataxin 10 ATTCT repeat  Ataxia and epilepsy 
SCA12 5q32 PPP2R2B  PPP2R2B CAG repeat  Ataxia, tremor 
SCA13 19q13.33 
KCNC3  KCNC3 MM  Ataxia, mental retardation 
SCA14 19q13.42 
PRKCG  PRKCG MM  Ataxia, myoclonus dystonia 
SCA17 6q27 TBP  TBP CAG repeat  Ataxia, chorea, psychiatric manifestations, dementia, epilepsy 
SCA18 7q31-q32  Unknown Ataxia, sensory neuropathy 
SCA19* 1p21-q21  Unknown Ataxia, myoclonus, cognitive impairment 
SCA20 11  Unknown Ataxia, disphonia 
SCA21 7p21.3-p15.1 Unknown Ataxia, parkinsonism 
SCA22* 1p21-q23  Unknown Ataxia 
SCA23 20p13-p12.2  Unknown Ataxia, sensory neuropathy 
SCA25 2p21-p15  Unknown Ataxia, sensory neuropathy 
SCA27 13q33.1 FGF14  FGF14 MM  Ataxia tremor mental retardation 
SCA28 18p11.22-q11.2  Unknown Ataxia, opthalmoplegia 
DRPLA 12p13.31 ATN1  Atrophin 1 CAG repeat  Ataxia, myoclonus, seizures, psychiatric manifestation, dementia  
  
Undefined** 16q22.1 
 PLEKHG4 Puratrophin 
1 5’ SNS  Ataxia, sensory neuropathy 
   ADCA II Variable similar presentation to ADCA plus the presence of 
pigmentary retinopathy 
SCA7 3p14.1 ATXN7  Ataxin 7 CAG repeat  Cerebellar ataxia, pyramidal signs, pigmentary maculopathy 
   ADCA III Relatively pure cerebellar ataxias where the degenerative 
process is limited to the cerebellum 
SCA6 19p13.13 
CACNAIA  CACNAIA CAG repeat  
Almost pure cerebellar ataxia (occasional dystonia or 
Parkinsonianism described) 
SCA5 11q13.2 SPTBN2  Beta-III spectrin D, MM  Almost pure cerebellar ataxia 
SCA11 15q14-q21.3 
SCA11  Unknown Almost pure cerebellar ataxia 
SCA15 3p24.2-pter 
ITRP1 ITRP1 D  Almost pure crebellar ataxia 
SCA16 8q23-q24.1  Unknown Almost pure cerebellar ataxia 
SCA24 1p36  Unknown Almost pure cerebellar ataxia 
SCA26 19p13.3  Unknown Almost pure cerebellar ataxia 
 
 
SCA3 or Machado-Joseph disease (MJD) 
Depending on ethnicity SCA3 accounts for between 21-56% of SCA cases
110
. Prevalence varies 
according to founder effects.  It is a polyglutamate (polyQ) disease caused by a CAG repeated 
expansion of the ATXN3 gene on chromosome 14q. The protein encoded by ATXN3, Ataxin-3, is a 
deubiquitinating enzyme that cleaves ubiquitin off substrates. It is felt that this enzyme’s function and 
thus biochemical pathways dependent on ubiquitin are affected in SCA3
111
.  The age of onset varies 
from childhood to late adult life and there is an inverse correlation between the number of CAG 
repeats and the age of onset and disease severity 
112
.  
The pathology includes atrophy of the middle cerebellar peduncles, dentate nucleus of the cerebellum 
and pontine nucei i.e cerebello-thalamo-cortical motor loops. The pathology also affects the 
substantia nigra, subthalamic nuclei (basal ganglia thalamocortical loops), red nuclei, anterior horn 
cells, motor cranial nerves. Additional pathology has been described in the somatosensory, auditory 
and occulomotor systems.  Brainstem involvement affecting dopaminergic and cholinergic system is 
also present. The corticospinal tract however is not severely affected and central motor conduction 
times have been found to be normal.  
110,113-115
 . 
Symptoms include progressive ataxic gait and balance and dysarthria. Associated with this are 
symptoms of spasticity, hyperreflexia and nystagmus. In some cases cerebellar-cognitive changes 
are also observed, namely deficits in memory, executive dysfunction, naming and attention; visuo-
spatial processing and calculation, however, appear spared
116
. In later stages there is opthalmoplegia 
and slowing of saccades; amyotrophy and dystonic posturing. There can also be peripheral nerve 
involvement leading to a loss of distal sensation and areflexia that is more prominent in older people. 
Difficulty falling asleep, increased nocturnal wakening is more common in older people with brainstem 
involvement and can be associated with central apnoea and restless legs syndrome
110
. 
  
The presenting symptoms vary with the age of onset and different types of presentation have been 
described (table x.3), type 2 being the most common seen in ~57-75% of cases. Earlier onset cases 
and those with large CAG repeat expansions tend to have signs of spasticity
113
. The presence of early 
UMN signs with minimal cerebellar signs can make SCA3 difficult to distinguish from HSP and this 
has been described as the type 5 presentation 
3,113,117
 
 
SCA3 Type Mean age of onset 
(Range) 
Symptoms 
1 25yrs Spasticity, rigidity, bradykinesia  
with minimal ataxia 
2 38 yrs (20-50) Progressive ataxia and upper motor 
neuron signs (spasticity , paresis) 
3 48 yrs (40-75) Ataxia and peripheral nerve involvement 
with amyotrophy and generalised areflexia 
4 Variable age of onset Parkinsonian phenotype 
5 25yrs (12-48) 
117
 “Pure” progressive spastic paraplegia 
 
Table x.3 Clinical and Subtype Clinical Characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box 4: Symptom Presentation and Balance dysfunction in SCA3 and SCA6 
Despite balance being an early and well-described symptom, the mechanistic underpinnings of balance impairment remain 
poorly understood. Tables 1-4 compare the differences between a relatively pure group of 16 people with cerebellar ataxia 
(SCA6) to four individual subjects with SCA3. These presentations outline the variability of SCA3 presentations and the 
multi-factorial potential for signs and symptoms to contribute to balance impairment, in contrast to SCA6 where the 
balance impairment involved is likely to solely be due to cerebellar disease. Table 1 highlights differences in clinical scores 
SCA 
type: 
Age: Sex
: 
Age at 
onset 
SARA 
(/40, 
most 
severe 
ataxia) 
Highest 
scoring 
element
s of 
SARA: 
Berg 
score 
(/56, best 
balance 
function) 
Falls in 
last 6 
months 
Loss of 
functional 
independence, 
(FIM score 
/126, best 
independence)
: 
Mobility 
aid use: 
Abnormal 
MMSE 
(score): 
SCA3
a 
40 m 28 17 Gait 31 Y (n=3, 
lost 
balance) 
Y (117) Y 
(rollator) 
N (24) 
SCA3
b 
53 f 45 2 Gait 56 N N (126) N N (30) 
SCA3
c 
49 M 35 14  Gait 20 Y (n=3, 
legs 
gave 
way/lost 
balance) 
Y (120) Y 
(sticks) 
N (24) 
SCA3
d 
54 f 40 27.5 Gait 5 Y (n=7, 
lost 
balance) 
Y (117) Y 
(WCH) 
Y (12) 
SCA6: 
Mean 
(SD) 
62.3 
(10.2) 
7m: 
9f 
52.2 
(16.4) 
12 (6.1) Gait 35.0 
(17.4) 
1.9 (2.1) Y 122.3 (4.7) None 
(n=8) 
Stick 
(n=5) 
Crutch 
(n=3) 
Rollator 
(n=2) 
WCH 
(n=2, 
outdoor 
only) 
Abnormal 
MMSE 
(score): 
Table 1 Functional overview of individual SCA3 cases contrasted to typical SCA6 group 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box 4 Continued  
Symptom Presentation and Balance dysfunction in SCA3 and SCA6 
As can be seen by table 2 people with SCA3 more frequently have abnormalities in upper motor neuron signs , sensory 
loss and spasticity / spasms. 
SCA type: 
Proprioceptive 
loss (hallux 
longus 
position in 
space test): 
Abnormal 
Babinski: 
Abnormal 
monofilament 
(<9/10): 
Muscle 
weakness 
(triceps 
surae), (/5, 
best muscle 
strength): 
Increase in 
tone 
(Ashworth 
scale, ankle 
PF): 
ROM 
restrictions: 
Spams 
(Penn 
spasm 
scale) 
SCA3a 
N N N (av 10) 
N (5/5 
bilateral) 
N (1/5 
bilateral) 
N N 
SCA3b 
N Y (absent) Y (av 8.5) 
N (5/5 
bilateral) 
N (1/5 
bilateral) 
Y (-5 DF 
bilateral) 
N 
SCA3c 
Y (bilateral) N Y (av 1) 
Y (4/5 
bilateral) 
Y (3/4 
bilateral) 
Y (-5 DF 
bilateral) 
Y (4) 
SCA3d 
Y (bilateral) Y (absent) Y (av 4) 
N (5/5 
bilateral) 
N (1/5 
bilateral) 
N Y (2) 
SCA6: 
Mean 
(SD) 
No No 
No (Mean: 9.9 
SD: 0.3) 
Mean:4.6 
SD: 0.6 
No No None 
 
Table 2 Individual SCA3 sensorimotor assessment contrasted to typical SCA6 group 
SCA 
type: 
Gait Stance Sitting 
balance 
Speech Finger 
chase 
(dysmetria) 
Nose to 
finger 
(tremor) 
Hand movements 
(dysdiado-
chokinesia) 
Heel shin 
(co-
ordination) 
Total BalSARA 
SCA3a 5 2 2 0 3 1 2 2 17 9 
SCA3b 1 0 0 0 0.5 0 0 0.5 2 1 
SCA3c 3 3 0 2 1 1 1 3 14 6 
SCA3d 6 5 2 3 3 3 2.5 3 27.5 13 
SCA6: 
Mean 
(SD) 
3 
(1.7) 
1.5 
(1.0) 
0.3 
(0.7) 
2.1 
(1.1) 
1.3 (1.0) 0.5 
(0.5) 
1.6 (1.0) 1.7 (1.2) 12.0 
(6.1) 
4.8 (3.1) 
 
Table 3 Individual SCA3 SARA scores contrasted to typical SCA6 group 
 
 
  
 
Symptomatic Management 
SCAs are progressively degenerative in nature and ultimately lead to death over a typical period of 15 
to 30 years. SCA6 is, however, an exception due to the late onset and slower progressive nature of 
the disease and is often not life limiting. No therapeutic strategies are as yet available to target 
primary disease pathways in those with SCA and therefore current management approaches involve 
designing treatments to alleviate symptoms.  
Recommendations for the symptomatic treatments of spasticity, parkinsonism, dystonia and cramps 
have been outlined and include benzodiazepines, baclofen and carbamazepine 
118,119
. A case study 
has described the use of botulinum toxin injections for lower limb spasticity and cramps that produced 
no side effects although the clinical benefits were not described
120
. In contrast botulinum toxin 
injections for associated cervical dystonia have been associated with dysphagia
121
. A double bind 
randomised controlled trial 
122
 of the antibiotics sulfamethoxazole and trimethoprim (co-trimoxazole) 
have not supported the improvements in spasticity and rigidity described by earlier smaller 
trials.
123,124
) . Some people with SCA3 can show levadopa-responsive dystonia and therefore patients 
should undergo a levadopa trial if dystonia is present. SCAs involving parkinsonian features, such as 
SCA2 and 3 (MJD) often respond to dopaminergic therapy, such as levodopa 
125-128
  and 
dopaminergic drugs can also be helpful in ameliorating restless legs to aid uninterrupted sleep 
128,129
 
130
. Amantadine is sometimes used to treat dystonia and bradykinesia  
128,131
 . Those experiencing 
muscle cramps, most commonly encountered in SCA3, can trial magnesium, chinine, quinine or 
mexiletine drug therapies 
132
. As with other SCAs and cerebellar disorders the pharmacological 
management of ataxia is limited
118,133
. Tandospirone may improve symptoms of ataxia, depression 
and insomnia
119
.  
Rehabilitation is recommended including physical therapy to address strength, balance and gait and 
offer advice on falls management as well as speech therapy and dietetics to address issues of 
dysphagia and dysarthria, to prevent aspiration pneumonia, weight loss and dehydration
134
. 
Maintenance of mobility and fatigue management with appropriate use of walking aids and 
wheelchairs is also required as the disease progresses  and it is recommended that these should be 
prescribed before falls cause fractures and long lasting immobilisation 
128
. Splints and orthoses may 
prevent trauma from over-supination or pain from over-extension of the knee
128
. No evidence exists 
however for the efficacy of these interventions leading to uncertainty and variability in approaches. 
Management recommendations for SCA3 are currently mainly based on the evidence base for 
treating people with Parkinson’s disease
111,135
.  
Autosomal Recessive 
Most autosomal recessive ataxias have symptoms of limb ataxia and impaired balance and walking. 
Additional signs include vertigo, dysphagia and diplopia 
136
. Unlike the autososomal dominant ataxia 
that present with associated extrapyramidal and pyramidal signs the autosomal recessive ataxias 
often have additional signs of sensorimotor neuropathy resulting in loss of proprioception and 
vibration sense
136
.  
  
Friedreich’s ataxia and Late onset Friedreich’s ataxia 
Friedreich’s ataxia (FRDA) is the most common autosomal recessive ataxia affecting 2 per 100,000. 
In ~98% of cases it is caused by a GAA repeat expansion on the Frataxin gene on chromosome 9q13. 
The age of onset is inversely related to the size of the repeat. Frataxin is localised to the 
mitochondrial matrix, it associated with iron metabolism and homeostasis. It is deficient in FRDA and 
increased mitochondrial iron accumulation, increased oxidative stress, impaired ATP production and 
cell death are seen 
136,137
.  
Degeneration of the dorsal columns, spinocerebellar tracts and dentate nucleus occurs in FRDA. It is 
characterised by progressive ataxia (affecting balance, walking limbs and speech) and sensory signs. 
Axonal sensory neuropathy results in areflexia and a loss of proprioception and vibration sense.  
Corticospinal tract involvement leads to paresis and extensor plantar responses
138
. Non – 
neurological involvement includes cardiomyopathy in ~50% and diabetes mellitus in ~10%.  With 
disease progression symptoms of kyphoscoliosis and pes cavus/equinovarus become prominent and 
these can affect respiratory function and walking
139
. 
Variations of the typical Friedreich’s ataxia presentation exist in ~10% of cases having a positive 
molecular test for Friedreich’s ataxia. People can show Friedreich’s ataxia with retained reflexes 
(FARR) and also late onset Friedreich’s ataxia (LOFA) or very late onset Friedreich’s ataxia  (VLOFA) 
where symptom onset occurs after 25 and 40 yrs respectively 
140
. Unlike typical Friedreich’s ataxia 
people with LOFA show signs of spasticity (40% of cases) and have retained reflexes (46% of cases)  
141,142
.   Non neurological symptoms such as cardiomyopathy, sphincter disturbances, scoliosis and 
pes cavus are less frequent in atypicaL FRDA 
142
. In VLOFA a spastic tetraparesis without marked 
ataxia or neuropathy has been described 
143
. Oculomotor abnormalities may be absent in atypical FA. 
People with LOFA have a slower progression and smaller GAA expansions. Another atypical FRDA is 
found in Acadian families from New Brunswick, Cananda. These individuals can have the same onset 
and symptoms as FRDA but without the involvement of cardiomyopathy and diabetes and may also 
show retained reflexes and spasticity. 
Management of FDRA 
There is currently no specific information on the management of LOFA and VLOFA. Therefore a brief 
overview of the management of FRDA will be provided. 
Co enzyme Q10 and Idebenone: 
Co-enzyme Q10 is a mitochondrial molecule that is part of the electron transfer chain. It is a potent 
antioxidant and can maintain other antioxidants such as vitamin E. Idebenone is a structural analog of 
co-enzyme Q10 but it is more water soluble and has a lower molecular weight and may thus show 
greater bioavailability
137
.  There is some evidence from randomised controlled trials in the USA and 
Europe to suggest improved cardiac function and maintenance / improvements in fine motor skills 
following idebenone
137
. However, as reviewed by Parkinson et al this seems to be dependent on the 
prescribed dose and baseline disease severity (improvements may be more marked in ambulant, less 
  
severe children). The impact on neurological signs and in particular functional ability and quality of life 
is unclear
137
. 
Symptomatic management 
Rehabilitation for FRDA involves a multi-disciplinary team including speech therapists and dieticians 
(to address communication issues, dysphagia, diabetes-management), occupational therapy, 
orthotists and physiotherapy
144
. A retrospective review of in-patient rehabilitation in people with FRDA 
found improvements in function (as measured by the functional independent measure) that continued 
to improve on discharge
145
.  Physiotherapy commonly consists of progressive resisted exercises and 
stretching 
146
. In addition mobility can be aided by aids (eg walking aids/ wheelchairs) and orthoses / 
shoes for pes cavus
147
. Orthopaedic management of scoliosis may also be required and early 
management of the pes cavus foot has been suggested
148
. 
Uptake of home rehabilitation programmes by people with FRDA can be sparse (~10%) 
146
. This 
could be related to perceptions of a lack of expertise by prescribing therapists about the condition as 
well as a lack of access to appropriate therapists. Issues around a lack of time and energy and the 
association of treatment with the presence of disability are further barriers highlighted
146
. The 
compliance with therapy may be increased by the use of interactive whole-body controlled video 
game technology. Intensive training over an 8 week period of balance and co-ordination skills resulted 
in improvements in ataxic symptoms, balance and walking
149,150
. Endurance training is feasible in 
people with FRDA and can lead to improvements in markers of cardiovascular fitness. A static 
exercise bike was used for training, which has the advantage of reducing balance requirements, and 
cardiac function was monitored during training 
151
.  
Intrathecal baclofen has been used to reduce painful spasms in a case with FRDA 
152
 whilst oral 
baclofen and botulinum toxin have been recommended for spasticity management
144
. There are no 
clinical trials or reports on the management of spasticity in late onset FRDA. 
 
Motor Neuron Disorders and Familial Amyotrophic lateral sclerosis 
Motor Neuron Disease: Amyotrophic lateral sclerosis (ALS) accounts for 70-90% of cases of Motor 
Neuron Disease and is characterised by predominant lower motor neuron (LMN) signs of weakness in 
combination with mild UMN signs of spasticity and brisk reflexes.  A minority of people with ALS, 
termed UMN-Dominant, have pyramidal signs and severe spino-bulbar spasticity with slight LMN 
signs. In 2-5% of people with Motor Neuron Disease there is exclusive involvement of UMNs termed 
primary lateral sclerosis. In contrast, people without any clinical or electrophysiological UMN signs 
and only LMN signs are labelled as progressive muscular atrophy. The remaining subtypes of MND 
are characterised by LMN signs affecting the bulbar muscles (Progressive bulbar palsy) or UMN 
involvement affecting the bulbar muscles (Pseudobulbar palsy)
153
. 
  
Amyotrophic lateral sclerosis  
Prevalence and Genetics 
ALS has a prevalence of 3.4-5.4 per 100,000.  The age of onset is usually in late adult hood (65yrs), 
and survival time is 2-3 yr for bulbar onset and 3-5 yrs for limb presentation onset. People with an 
UMN-Dominant presentation have a longer survival time 
153
.  
Familial ALS (FALS) is diagnosed where there is a first or second degree relative of the index case. 
FALS accounts for 4.6% of cases of ALS 
154
. Familial ALS is usually inherited in an autosomal 
dominant manner but autosomal and recessive patterns of inheritance have been described. 
Mutations in the SOD1 gene, the first gene on chromosome 21 found to cause FALS, accounts for 20% 
of Familial ALS cases. The gene C9ORF72 is linked to chromosome 9p21 and makes up ~43% of 
FALS and 7% of sporadic cases. This form of  FALS is associated with Frontotemporal dementia.  
The genes TARDBP, FUS, VCP,UBQLN2 and OPTN comprise the majority of the remaining genes 
causing FALS 
155,156
.  
 
Pathology 
ALS is associated with degeneration of the corticospinal tract and alpha and gamma motor neurons 
and interneurons in the spinal cord and Betz cells within the primary motor cortex. There is additional 
degeneration in the deep frontal and temporal white matter, corpus callosum, brainstem (including 
serotonergic neurons) and motor nuclei of the basal ganglia 
157
. People with ALS and an expansion in 
the gene C9ORF72 have additional pathology in the frontal cortex and hippocampus (CA4 area) in 
keeping with the association of frontotemporal dementia 
156
. 
Hyperexcitability in the motor cortex is seen early on in the disease course; there is a reduction in 
GABAA-mediated short interval intracortcal inhibition (SICI); a reduced motor threshold and an 
increase in the cortical silent period, which is mediated in part by GABAB interneurons. Cortical 
hyperexcitability is felt to reflect degeneration of inhibitory interneurons in the motor cortex and may 
contribute to the presence of positive symptoms such as cramps, fasciculations, fibrillations, sharp 
waves and spasticity.  With disease progression there is a reduction in cortical excitability reflecting 
degeneration of corticomotorneuronal pathways
158
.  
Signs of hyperexcitability in the motor system such as the UMN positive signs are poor prognostic 
indicators. In SOD1 carriers cortical hyperexcitability can be seen prior to symptom onset and is 
associated with early weakness
159,160
. The reduction in SICI correlates with disease duration and 
motor deficit. It is hypothesised that cortical hyperexcitability can alter glutamate metabolism and lead 
to a dying forward of connected anterior motor neurons. An alternate hypothesis is that the 
hyperxcitability reflects a compensatory process that aims to increase central drive to the 
degenerating LMNs
158
. 
  
Clinical Presentation 
In ALS the onset of symptoms is usually focal weakness in the proximal or distal upper or lower limbs. 
Weakness develops in the other segments and limbs and this may be accompanied by bulbar and 
respiratory weakness.  On examination muscle fasciculations are visible. Upper limb symptoms are 
associated with bulbar signs (dysphagia and dysarthria)
161
. The degree of lower limb weakness 
predicts the level of walking ability (eg independent in the community, home ambulation, unable)
162-164
. 
Loss of ambulation occurs when the lower limb strength was on average 13.7% (±7.4) of the predicted 
normal level 
162
.  In one cohort loss of ambulation occurs on average after 46.7 months, about 11-15 
months after  provision of gastrostomy and Non Invasive Ventilation
165
. In people with genetic linkage 
to chromosomes 9p21 and an expansion in the gene C9ORF72 there are associated signs of 
frontotemporal dementia in 35% of cases including  personality change, irritability, obsessions, poor 
insight, and deficits in frontal executive tests 
156,166
. In many people painful cramps and flexor spasms 
can occur in the latter stages. Bulbar symptoms may be UMN and LMN in nature. Tongue movements 
may be slow due to spasticity and fasciculations and wasting of the tongue may be present. The jaw 
jerk may be brisk especially with bulbar onset disease. Respiratory muscle weakness can lead to 
dyspnoea on exertion, orthopnoea, disturbed sleep, morning headaches, daytime somnolence, weak 
cough and paradoxical abdomen movements 
153
. Death is usually due to respiratory failure and  
pulmonary complications. 
Spasticity is present in ALS as determined using clinical and electrophysiological measures (ie the H 
reflex) 
167
 
168
. However, upper motor neuron signs can be difficult to elicit in ALS with only 50% of 
cases showing an extensor plantar response 
157
. Spasticity is often hard to detect in weak muscles in 
ALS 
157
. This may reflect the co-occurrence of lower motor neuron signs that mask patterns of cortico-
spinal tract induced paresis and enhanced tendon reflexes. LMN signs are not seen in progressive 
lateral sclerosis and here spasticity is more marked
157
. In addition interneuronal degeneration within 
the spinal cord in ALS could also limit the emergence of hyperexcitable tendon reflexes 
157
. Direct 
pathology affecting the Renshaw cells within the spinal cord, for example, may explain why the 
Renshaw-mediated recurrent inhibition is reduced to a greater extent than seen after spinal cord 
injury
168
.   
Rigidity, felt as an increased resistance of a limb to movement in both directions, can also be present 
in ALS. Extrapyramidal signs as indicated by rigidity and a shortening reaction were assessed in a 
selected cohort of people with ALS (n=39) who had stiffness (> 2 Ashworth in both legs) but minimal 
weakness (at least 4/5 MRC manual testing). People who met this inclusion criterion made up 17% of 
the total sample assessed.  In this subsample extrapyramidal signs in combination with spasticity 
were seen in 69% with the remainder presenting with spasticity alone
169
.  People with mixed rigid-
spasticity presentation had worse balance, more retropulsion and more severe neck stiffness
169
. The 
presence of extrapyramidal signs is reflected in the reduced dopaminergic activity assessed using 
PET and reduced D2-receptor binding as assessed using SPECT
170-172
. As there are large 
corticostriatal connections, striatal involvement may be caused by glutamate excitotoxicity. 
  
In ALS degeneration of serotonergic (5-HT) neurons that project to the spinal cord is observed post 
mortem and in the SOD1 animal model 
173
 . In spinal cord injury loss of serotonergic projections from 
the brainstem dorsal raphe nuclei leads to secondary up-regulation of 5HT receptors on lower motor 
neurons that results in hyperexcitability, plateau potential generation and spasticity 
174,175
. Therefore, 
the loss of serotonergic neurons in ALS may underlie the development of spasticity.   
The involvement of tracts other than corticospinal tract in the genesis of spasticity in ALS  is 
underlined by the fact that corticospinal tract degeneration can be seen in 50% of people with a 
clinical diagnosis of progressive muscle atrophy who had no UMN signs when alive 
176
 Therefore, 
findings such as a correlation between precentral gyrus degeneration, as measured by DTI, and  
spasticity
177
 may simply reflect the co-occurrence of motor cortex pathology and spasticity in more 
severe cases of ALS and not reflect a causative link. 
Interventions 
Disease modifying therapy 
Riluzole prolongs median survival by 2-3 months if taken for 18 months (100mg) in people with 
clinically definite ALS and symptoms of less than 5 years who are under 75yrs and have a forced vital 
capacity >60% 
178
. Riluzole partly resolves the reduction in SICI and may act by inhibiting glutamate 
release and reducing cortical hyperexcitability
179
. In addition effects on peripheral nerve function (a 
reduction in superexcitability and refractoriness) have been reported
179
 
Symptomatic Management 
Respiratory management: Monitoring of respiratory function using force vital capacity(FVC), sniff 
nasal inspiratory pressures and nocturnal oximetry is important as respiratory insufficiency is the 
major cause of death. Criteria for starting non-invasive ventilation (NIV) are outlined in table x.2. NIV 
increases survival and quality of life. NIV is usually initially used for nocturnal hypoventilation with 
support during the day provided with increasing symptoms 
153
  
 
 
 
 
 
 
 
 
 
  
 
Symptoms related to respiratory muscle weakness. At least one of: 
• Dyspnoea 
• Orthopnoea 
• Disturbed sleep (not caused by pain) 
• Morning headache 
• Poor concentration 
• Anorexia 
• Excessive daytime sleepiness (Epsworth Sleep Score> 9) 
 
AND Evidence of EITHER: 
significant nocturnal desaturation on overnight oximetry 
OR 
 
Table x.4: Suggested criteria for non-invasive ventilation (NIV): Provisional European consensus 
criteria for NIV (European ALS/MNDConsortium and European Neuromuscular Centre workshop on 
non-invasive ventilation in MND, May 2002) [with permission from Leigh et al. 2003] 
 
Nutritional management: Dysphagia and upper limb weakness can lead to aspiration, malnutrition, 
weight loss and dehydration 
153
 . Early management of dysphagia includes dietary advice, alteration of 
food consistency and teaching swallowing techniques. Due to an ~10% increase in  the metabolic rate 
people with ALS require higher calorie intake
180
. Supplementary enteral feeding is recommended if 
the body weight falls below 10% of a person’s pre-diagnostic weight. A PEG (percutaneous 
endoscopic gastrostomy) is the usual option for enteric feeding. However, insertion does require 
sedation and so may compromise respiratory function and should be performed before the FVC is 
<50%. Insertion of PEG under NIV assistance or percutaneous radiologic gastrostomy / radiologically 
inserted gastrotomy under these conditions may be required
153
.  
Spasticity and Rigidity in ALS: Oral medications such as baclofen and gabapentin are not always 
effective in relieving spasticity and pain associated with spasms 
181,182
. Side effects such as weakness, 
sleepiness and fatigue have also been described with higher doses of oral baclofen
183
. In these cases 
the effects of Intrathecal baclofen has been explored. In a retrospective assessment of 6 cases who 
had ALS for a mean of 47.4 months, ITB reduced pain in 75% of people with the degree of pain relief 
being predicted by the response to a preoperative bolus test dose
184
. In two other cases ITB was also 
associated with reduction in painful spasms
183,185
  
Exercise in ALS: Exercise trials in early-stage ALS have been systematically reviewed by Lui et al 
2009 
186
. Exercise regimes consisted of treadmill training and moderate progressive resisted 
exercises and stretches. Although small to moderate effect sizes were found favouring the 
intervention (eg for FVC, fatigue, strength and function) the variability of the effect was very large and 
  
overall the results are inconclusive to date.  Reductions in spasticity have been described following 
exercise but only after the first 3 months with no effect being seen after 6 months between the no 
exercise control group and the intervention group 
187
.  
More recently the feasibility of supported treadmill training has been investigated in ALS (n= 9). 
People undertook an 8 week program consisting of x3/week training for 30 minutes where 5 minutes 
of exercise were interspersed with 5 minutes of rest. There was a 33% drop out but improvements 
were seen in walking over 6 minutes and fatigue rating with no deterioration in perceived function, 
FVC or muscle strength which showed non-significant improvements
188
. 
Cortical stimulation: Cortical hyperexcitability is felt to cause a dying forward of connected anterior 
motor neurons in ALS and is thus a potential target for therapy
158
. Repetitive cortical stimulation using 
TMS has been used to reduce cortical hyperexcitability. Other groups have used high frequency 
transcranial excitatory stimulation as there is evidence from animal studies that this may have a 
neuroprotective effect by increasing brain derived neurotrophic factor (BDNF) expression. Synapse-
specific activity has been shown to regulate BDNF transcription, transport and secretion and 
trafficking of its receptor.  BDNF in turn is felt to regulate synaptic efficacy and growth of dendrites 
and axons; processes that underpin synaptic plasticity
189
. There is evidence that a single nucleotide 
polymorphism in the BDNF gene can affect the response to r TMS in healthy participants and post 
stroke 
190,191
. Theses differences in people’s responsiveness to stimulation may underlie the variability 
in the results seen; a Cochrane review of randomised controlled trials of cortical stimulation studies in 
ALS  till 2010 found no evidence of effect in the trials performed to date 
192
.   
Leukodystrophies 
The leukodystrophies are inherited myelin disorders affecting  myelin development and maintenance 
in the central nervous system. A classification of the leukodystrophies is given below with examples of 
the more common types 
193
.  Up to half of people with leukodystrophies do not get a specific diagnosis. 
The age of onset varies with the type. The involvement of white matter tracts commonly leads to 
spasticity and UMN signs although reduced limb stiffness (hypotonia) can be seen e.g. in childhood 
onset. Extrapyramidal signs and ataxia may also be present.  Impaired swallowing, respiration and 
cognition, and epilepsy may also be seen
193,194
.  
Demyelinating and Dysmyelinating Disorders 
 X Linked Adrenoleukodystrophy  
 Krabbe Disease 
Hypomyelinating Disorders 
 Pelizaeus-Merzbacher Disease 
 Alexander Disease   
Spongiform Disorders  
  
 Canavan Disease  
Cystic Disorders 
 Vanishing white matter disease   
Adrenoleukodystrophy 
Prevalence and Genetics 
Adrenoleukodystrophy (ADL) is an X linked recessive disorder characterised by adrenal insufficiency 
and demyelination in the central and peripheral nervous system. They are caused by a defect in a 
peroximal membrane transporting protein leading to the accumulation of very long chain fatty acids in 
tissues and plasma. De novo mutations occur in 19% of cases (Horn 
195
 et al 2013). Clinical severity 
is not related to the length of the very long chain fatty acids. It occurs in 0.5-3.3 per 100000 males and 
there are several forms.  
Clinical Presentation 
The cerebral inflammatory presentation can start during childhood (3-10yrs), adolescence(11-21 yrs) 
or adult life (>21 yrs) onset. It accounts for ~50% of cases and is characterised by perivascular 
lymphocyte infiltration in parieto-occipital region (85% of cases) or frontal lobe region (15% of 
cases)
196
.  Child ADL has symptoms of ataxia, spasticity, dysphagia, deafness, visual deficits, 
personality changes and in ~30% seizures
197
. Neurological deterioration occurs over 2-3 years until 
there is complete disability, a vegetative state and death.  
Adrenomyeloneuropathy (AMN) is seen in ~45% of cases
196
. Here onset is 28 (+/- 9) yrs. It is 
characterised by non-inflammatory distal axonal loss and secondary demyelination affecting the 
dorsal columns and corticospinal tracts and a peripheral neuropathy 
198
. It is characterised primarily 
by lower extremity spasticity, paresis and loss of vibration sensibility that affects walking and 
balance
198
. Bladder and bowel function can also be affected.  Sensory loss can appear in isolation or 
with symptoms of paresis and spasticity
198
. In ~20% of cases there is additional cerebral pathology. 
Somatosensory and brainstem EPs and MEPs, transcortical, long latency stretch reflexes from the 
hand  are prolonged and/or reduced in amplitude in keeping with the pathology affecting the dorsal 
columns and corticospinal. 
199-202
  
In AMN postural sway is increased in amplitude and correlates with the degree of lower limb 
weakness and sensory loss
198,203
. Walking is slower than normal but the pattern is relatively 
unimpaired in patients with isolated sensory loss. Strength loss and spasticity result in a crouch and 
stiff knee gait with reduced ankle motion. A cross sectional study of 142 people with AMN found that 
lower limb strength is the main predictor of functional ability. Vibration thresholds also predicted 
functional ability whilst ankle spasticity was correlated with walking velocity and timed up and go test 
203,204
.  
AMN symptoms can mimic Hereditary / familial SP 
4,5,205,206
 and symptoms of ataxia mimicking a 
spinocerebellar degeneration have also been described
6,7
 Differential diagnosis is important in cases 
  
of sporadic SP and where male to male transmission is absent as the more severe cerebral childhood 
form arises from the same gene mutation as AMN
4
  
 
Primary adrenal insufficiency (“Addison only presentation”) comprise the remaining 20% of cases. 
Here people do not have neurological symptoms. Symptom free males with the gene deficit have 
been described.  
Females are carriers and can exhibit symptoms of adrenal failure. In 55-63% of cases neurological 
symptoms akin to AMN are seen with/without peripheral neuropathy (~57%) and a high incidence of 
fecal incontinence (28%) 
207
. The age of symptom onset in females is a decade later than males 
(~38yrs), the symptoms milder and the progression slower. Cerebral involvement can be seen in 
female carriers. 
Interventions 
Management of AMN consists of the following 
196,208
: 
1) Adrenal hormone replacement therapy for those with adrenal insufficiency 
2) Dietary therapy: Lorezo’s oil (a 4:1 mixture of glyceryl trioleate and glyceryl trierucate). and 
moderate reduction of fat intake can lower VLCFA in the plasma
196
. The therapy does not 
slow progression rate of those who are already symptomatic especially if they have the 
cerebral inflammatory presentation. Open label trials suggest that Lorezo’s oil can slow the 
progression of pure AMN and can be preventative in asymptomatic boys. 
3) Hematopoietic stem cell transplantation has been reported to be effective in presymptomatic 
or early symptomatic childhood cerebral ADL 
Treatments of symptoms such as spasticity have only been reported in case reports for example for 
the use of dantrolene effect in AMN 
209
 and ITB in cerebral child ADL
197
.  
 
Summary 
The hereditary myelopathies represent a relatively rare and diverse group of conditions. As such 
research into the pathophysiology of a condition is often sparse and requires multi-centre and multi-
national approaches. An understanding of the underlying genetics of each condition over time could 
lead to disease modifying therapies and improvements in the information provided during genetic 
counselling.  
In many cases spasticity and paresis are seen in combination with a variety of other signs such as 
ataxia, extrapyramidal signs (rigidity, bradykinesia,tremor) and sensory loss. Symptom onset can 
occur at various times throughout life and this may result in differences in the presence and relative 
impact of secondary complications such as contracture, increased passive stiffness and bony 
deformity. Spasticity is therefore just one of a multitude of impairments that may impact on functional 
  
ability. Although spasticity and hypertonia can limit mobility it may have a positive impact on stability 
and therefore should not be considered an obligate target for treatment.   Future work will help to 
elucidate the relative importance of different impairments in limiting function and quality of life and the 
effectiveness of symptomatic interventions.  
 As the myelopathies are hereditary there will be symptom progression over time. Differences in the 
rate of disease progression and the severity and extent of CNS damage will presumably affect the 
ability of the neuromusculoskeletal system to adapt to environmental demands (eg training and 
rehabilitation) and therefore the effectiveness of interventions that aim to restore functional ability. In 
cases where the adaptability and plasticity of the system is limited compensatory techniques that aim 
to maintain / improve functional ability through the use of altered strategies and aids and adaptations 
may be more appropriate. Which approach is adopted and the overall goals of treatment may vary 
over the disease trajectory in an individual and with the aims of the patient; their family and carers. A 
greater understanding of these issues will lead to improved symptomatic management. 
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